For Jon Lubecky, the scars on his wrists are a reminder of the years he spent in mental purgatory. He returned from an Army deployment in Iraq a broken man. He got every treatment offered by Veterans Affairs for post-traumatic stress disorder. But they didn't stop him from trying to kill himself - five times. Finally, he signed up for an experimental therapy and was given a little green capsule. The anguish stopped. Inside that pill was the compound MDMA, better known ... as ecstasy. That street drug is emerging as the most promising tool in years for the military's escalating PTSD epidemic. The MDMA program was created by a small group of psychedelic researchers who had toiled for years in the face of ridicule, funding shortages and skepticism. But the results have been so positive that this month the Food and Drug Administration deemed it a "breakthrough therapy" - setting it on a fast track for review and potential approval. Only two drugs are approved for treating PTSD: Zoloft and Paxil. Both have proved largely ineffective. By giving doses of MDMA at the beginning of three, eight-hour therapy sessions, researchers say they have helped chronic PTSD patients process and move past their traumas. In clinical trials with 107 patients closely monitored by the FDA, 61 percent reported major reductions in symptoms - to the point where they no longer fit the criteria for PTSD. Follow-up studies a year later found 67 percent no longer had PTSD.